CureVac’s Final Chapter: A Bridge to BioNTech Nears Completion

CureVac NL0015436031

The investment narrative surrounding CureVac has undergone a fundamental shift. The company's shares no longer trade on the prospects of its independent pipeline but have transformed into a temporary vehicle tied to a single event: its impending acquisition by rival BioNTech. For shareholders, the focus is now squarely on the technical transition out of the market and into BioNTech holdings.

At the core of this shift is the agreed-upon acquisition by Mainz-based BioNTech. Following the successful tender offer, CureVac's valuation has effectively detached from its own clinical trial updates or product announcements. Instead, its share price moves in direct correlation with BioNTech's stock.

This link is defined by a fixed exchange ratio of 0.05363 BioNTech shares for each CureVac share. Consequently, holding CureVac stock today represents a derivative economic exposure to BioNTech. The current trading level near $4.48 USD largely mirrors the calculated value of this exchange ratio. Any movement in BioNTech's share price is therefore immediately reflected in CureVac's.

Countdown to Delisting

Integration efforts are proceeding rapidly alongside this financial linkage. The timeline for remaining shareholders is clearly defined. According to current plans, the final trading day for CureVac stock is scheduled for January 5, 2026.

Subsequent to this delisting, the public listing will cease. Any remaining shares are expected to be settled via a squeeze-out procedure or automatically converted into BioNTech American Depositary Receipts (ADRs). From an investor's perspective, a CureVac position is now essentially a transitional holding on the path to a direct stake in BioNTech.

Key Timeline:
- Present: Trading continues under the shadow of the acquisition.
- January 5, 2026: Anticipated last trading day for CureVac shares.
- Thereafter: Delisting and conversion or cash settlement of remaining holdings.

Pre-Delisting Volatility and Arbitrage

Despite the clear framework of the takeover, the stock exhibited notable volatility in December. On December 22, the shares hit a 12-month low of $4.01 USD before staging a technical recovery to the current level of approximately $4.48 USD. This rebound is fundamentally an arbitrage play, as market participants capitalize on the differential between the market price and the calculated takeover value based on the exchange ratio.

This period was accompanied by elevated trading volumes, with over one million shares changing hands in individual sessions. This activity suggests institutional investors and arbitrage funds are finalizing their positions ahead of the delisting.

A One-Off Gain Provides Financial Cushion

Operationally, CureVac has entered a transitional phase. However, its most recent financial results included a significant, albeit non-recurring, item. The company reported a net profit of 273.2 million euros for the third quarter of 2025—a sharp departure from previous periods of losses.

This result was not driven by surprise operational success but by a one-time payment of $370 million USD. The funds originated from a legal settlement with BioNTech, Pfizer, and GSK related to patent disputes. This special payment stabilized CureVac's liquidity position and secured financing through the completion of the acquisition. It holds minimal relevance for the stock's independent valuation, however, as its future price trajectory is now entirely dependent on BioNTech.

Conclusion: A Transitional Instrument

CureVac's equity has evolved from a speculative mRNA biotech story into a technical merger arbitrage instrument. Its price moves tightly along the parameters set by the BioNTech deal, with no significant independent catalysts expected. For existing shareholders, the investment now serves as a bridge to a BioNTech stake, complete with a defined roadmap culminating in the projected final trading day on January 5, 2026.